Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Interest Income Expense
Ondine Biomedical Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Interest Income Expense
CA$63k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Interest Income Expense
$327k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Interest Income Expense
$5.2m
|
CAGR 3-Years
231%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Interest Income Expense
-CA$3.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-97%
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Interest Income Expense
CA$32.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
MedMira Inc
XTSX:MIR
|
Interest Income Expense
-CA$942.2k
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Interest Income Expense?
Interest Income Expense
63k
CAD
Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Interest Income Expense amounts to 63k CAD.
What is Ondine Biomedical Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-92%
Over the last year, the Interest Income Expense growth was -92%.
You don't have any saved screeners yet